Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I appreciate your honesty I will check it out if everything falls in place like you are expecting, where do you see the PPS in one year?Remember you have quite a bit shares out on this stock!I would like to call their transfer agent in California, to check on the share structure do you have their Number or anyone have their Number? Funny thing with Pinkies, the rules and the numbers change in the blink of an eye...one has to call the Transfer Agent every day. I know they took down 950m to 350m it was on 18th April 2011.
Red flagging DANGERS in the penny market and NXOI is right on top of the list!
Anyone and please no BS!!!Red flagging DANGERS in the penny market all the time!
Give me a reason to buy I'm looking at this and I don't see much going on.
Watch this week RXPC!
Just because shares are authorized doesn't mean they're issued!Easy money next 2 weeks..
JUST TODAY OVER 8,127,184 SHORT!
Insider Trading Warning
This company may not be making material information publicly available.
http://www.otcmarkets.com/stock/SKZW/quote
There's been hype on this stock since 2006 go figure!http://investorshub.advfn.com/boards/read_msg.aspx?message_id=10893340
So true!
Thanks for your honest opinion!
If you give your honest opinion which I doubt to many people on this message board can do, where do you see ELTP PPS by end of the year?
Huge potential! From what I understand about this company!
Thanks a lot! Thank you for honest opinion good luck to ya, thanks for playing fair I did some home work I will be up on Monday to get in!
Are you waiting for news and where do you see this by end of the year?
I agree!
Sell this and buy ELTP the move up is very soon!
I don't like this if this is what is going on!http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_C/threadview?m=tm&bn=89049&tid=21&mid=26&tof=1&frt=2
Best of luck with whatever you decide, all be out at .30 holding 400 thousand sh....
Holding on well might see move up to .30 soon!
Y ?
NICEEEEEEEEEEEEEEEEEEEEEEE! JUST BOUGHT SOME HOLDING ON!!
Looks like it can go lot higher.
Where do you see this headed?
Getting interested in this stock any info will help!
ELITE PHARMACEUTICALS » Cost of Saleshttp://www.wikinvest.com/stock/ELITE_PHARMACEUTICALS_%28ELTP%29/Data/Cost_of_Sales
WOW! GOOD FIND!
Keep us in the loop.
We have a real deal!
If you know it explain ?
I Disagree 2 all I know is someone is getting this stock with a big discount very well orchestrated these guys are not stupid!My gut feeling says Actavis!
Epic is a $400 million revenue company. With the OS at 243 million shares and with current share price at .155 that will put the PPS at $1.80 with a reverse merger and that's with out PE ratio.
Link to where I got the $400 million revenue company:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_E/threadview?m=tm&bn=99215&tid=71595&mid=71595&tof=8&frt=2
I agree!
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal 2011
Revenues Up 34% - Operating Profit Achieved
NORTHVALE, N.J., Feb. 14, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release product formulations, announced results for the fiscal third quarter ended December 31, 2011.
For the third quarter, consolidated revenues were $1.2 million, an increase of 34% compared with last year's third quarter, with substantially all revenues being derived from the manufacture, sale and lab services related to the Lodrane family of products.
Profits from operations were $72,931 for the third quarter, as compared to last year's third quarter operating losses of $509,893. This marks the first quarter in which the company has achieved an operating profit and is indicative of results achieved pursuant to the continuing efforts by management to increase manufacturing efficiency and reduce operating costs.
GAAP net income, including non-cash revenues and expenses relating to the accounting treatment of preferred share derivatives and the fair value of warrant derivatives, was $5.9 million. Basic net income was $0.06 per share and fully diluted net income was $0.02 per share.
For the first nine months of fiscal 2011, cash flow from operations was a positive $318,457, compared to a negative operating cash flow of ($1.1 million) for the same period last year. Approximately $400,000 of cash has been invested in the purchases, previously announced, of three approved ANDA's, and in the continued expansion and improvement of Elite's manufacturing facilities. Total net cash flow for the first three quarters, inclusive of cash from operations and cash used in investing and financing activities was a negative $162,993. Our cash balance as of December 31, 2010 was $415,194.
The company is currently in discussions to license its once daily oxycodone product, ELI-154, to a European marketing partner and is progressing towards scale-up in the development of its abuse-resistant formulation of oxycodone, ELI-216.
The Company will host a conference call to discuss the results of operations and provide an update on recent business developments today at 10:00 AM EST. Company executives will also conduct a question and answer session following their remarks.
To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until February 28, 2011 by dialing:
Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840
Financial Statements
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
ASSETS